Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · participants undergoing surgery with peripheral nerve block
3 findings from 1 review
no estimate extracted
3 studies · 172 participants
Low
no estimate extracted
3 studies · 162 participants
Low
no estimate extracted
5 studies · 257 participants
Low
Duration of sensory block (we included all studies describing duration of sensory block regardless of how it was described) · participants undergoing surgery with peripheral nerve block
1 finding from 1 review
Incidence of serious adverse events (we used the NIH definition of adverse events. A serious event includes death, a life‐threatening event that requires hospitalization or prolonged hospitalization, disability or congenital anomaly) · participants undergoing surgery with peripheral nerve block
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · adults with renal vasculitis
Intravenous immunoglobulin showed no clear difference in death compared with placebo (low certainty).
1 finding from 1 review
Kidney function · adults with renal vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dialysis · adults with renal vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Response at 3 months · adults with renal vasculitis
Intravenous immunoglobulin may leads to higher response at 3 months compared with placebo (low certainty).
1 finding from 1 review
Relapse at 3 months · adults with renal vasculitis
Intravenous immunoglobulin showed no clear difference in relapse at 3 months compared with placebo (low certainty).
1 finding from 1 review
Adverse events · adults with renal vasculitis
Intravenous immunoglobulin may leads to higher adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious infection · adults with renal vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with fulminant hepatic failure secondary to paracetamol (acetaminophen) overdose
Intravenous acetylcysteine may leads to lower mortality compared with placebo (low certainty).
1 finding from 1 review
SAEs · NSTI
Intravenous immunoglobulin showed no clear difference in serious adverse events (SAE) compared with placebo (low certainty).
1 finding from 1 review
Survival time · NSTI
1 finding from 1 review
Assessment of long‐term morbidity · NSTI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · NSTI
Intravenous immunoglobulin showed no clear difference in mortality compared with placebo (low certainty).
1 finding from 1 review
Muscle strength · people with inclusion body myositis
2 findings from 1 review
Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
Change in handgrip strength at 6 months (%) ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
Significant adverse events · people with inclusion body myositis
1 finding from 1 review